Use of Anti TNF-α Therapy in Systemic VasculitisTalal Al-Mteri1, Fatma Al-shaiki2, Shahd Hafiz1, Rabab Taha3, Omar Fathaddien4 and Hani Almoallim1,3,5*
- *Corresponding Author:
- Hani Almoallim
Alzaidi Chair of Research in Rheumatic Diseases
Faculty of Medicine, Umm-Al Qura University
Makkah, Saudi Arabia
Email: [email protected]
Received Date: November 08, 2016; Accepted Date: January 01, 2017; Published Date: January 23, 2017
Citation: Al-Mteri T, Al-shaiki F, Hafiz S, Taha R, Fathaddien O, et al. (2017) Use of Anti TNF-α Therapy in Systemic Vasculitis. J Vasc 3:119. doi: 10.4172/2471-9544.1000119
Copyright: © 2017 Al-Mteri T, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
There are several vascultic disorders still labeled as difficult-to-treat cases. Effective treatment for those patients is warranted to reduce the mortality and morbidity that resulting from these disorders. An extensive review for the literatures that addressed using of ant TNF-alpha in several vascultic disorders was conducted. Use of anti TNFalpha agents is a promising modality in several vascultic disorders. Despite lacking well-conducted randomized controlled trials, more open-label studies are required to examine in-depth the safety and efficacy of those agents.